| Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial SA Harrison, MR Bashir, CD Guy, R Zhou, CA Moylan, JP Frias, ... The Lancet 394 (10213), 2012-2024, 2019 | 546 | 2019 |
| NASH leading cause of liver transplant in women: updated analysis of indications for liver transplant and ethnic and gender variances M Noureddin, A Vipani, C Bresee, T Todo, IK Kim, N Alkhouri, ... Official journal of the American College of Gastroenterology| ACG 113 (11 …, 2018 | 504 | 2018 |
| Lipotoxicity in nonalcoholic fatty liver disease: not all lipids are created equal N Alkhouri, LJ Dixon, AE Feldstein Expert review of gastroenterology & hepatology 3 (4), 445-451, 2009 | 480 | 2009 |
| Adipocyte apoptosis, a link between obesity, insulin resistance, and hepatic steatosis N Alkhouri, A Gornicka, MP Berk, S Thapaliya, LJ Dixon, S Kashyap, ... Journal of Biological Chemistry 285 (5), 3428-3438, 2010 | 416 | 2010 |
| A randomized, controlled trial of the pan-PPAR agonist lanifibranor in NASH SM Francque, P Bedossa, V Ratziu, QM Anstee, E Bugianesi, AJ Sanyal, ... New England Journal of Medicine 385 (17), 1547-1558, 2021 | 358 | 2021 |
| Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: results from randomized phase III STELLAR trials SA Harrison, VWS Wong, T Okanoue, N Bzowej, R Vuppalanchi, ... Journal of hepatology 73 (1), 26-39, 2020 | 349 | 2020 |
| Ultrasonographic quantitative estimation of hepatic steatosis in children with NAFLD A Shannon, N Alkhouri, C Carter-Kent, L Monti, R Devito, R Lopez, ... Journal of pediatric gastroenterology and nutrition 53 (2), 190-195, 2011 | 332 | 2011 |
| Suboptimal reliability of liver biopsy evaluation has implications for randomized clinical trials BA Davison, SA Harrison, G Cotter, N Alkhouri, A Sanyal, C Edwards, ... Journal of hepatology 73 (6), 1322-1332, 2020 | 312 | 2020 |
| Neutrophil to lymphocyte ratio: a new marker for predicting steatohepatitis and fibrosis in patients with nonalcoholic fatty liver disease N Alkhouri, G Morris‐Stiff, C Campbell, R Lopez, TAR Tamimi, L Yerian, ... Liver International 32 (2), 297-302, 2012 | 299 | 2012 |
| Apoptosis in nonalcoholic fatty liver disease: diagnostic and therapeutic implications N Alkhouri, C Carter-Kent, AE Feldstein Expert review of gastroenterology & hepatology 5 (2), 201-212, 2011 | 270 | 2011 |
| Effects of belapectin, an inhibitor of galectin-3, in patients with nonalcoholic steatohepatitis with cirrhosis and portal hypertension N Chalasani, MF Abdelmalek, G Garcia-Tsao, R Vuppalanchi, N Alkhouri, ... Gastroenterology 158 (5), 1334-1345. e5, 2020 | 266* | 2020 |
| NAFLD in children: new genes, new diagnostic modalities and new drugs V Nobili, A Alisi, L Valenti, L Miele, AE Feldstein, N Alkhouri Nature reviews Gastroenterology & hepatology 16 (9), 517-530, 2019 | 254 | 2019 |
| Prevalence of nonalcoholic steatohepatitis-associated cirrhosis in the United States: an analysis of national health and nutrition examination survey data MN Kabbany, PKC Selvakumar, K Watt, R Lopez, Z Akras, N Zein, ... Official journal of the American College of Gastroenterology| ACG 112 (4 …, 2017 | 247 | 2017 |
| An apoptosis panel for nonalcoholic steatohepatitis diagnosis TIAR Tamimi, HM Elgouhari, N Alkhouri, LM Yerian, MP Berk, R Lopez, ... Journal of hepatology 54 (6), 1224-1229, 2011 | 235 | 2011 |
| Noninvasive tests accurately identify advanced fibrosis due to NASH: baseline data from the STELLAR trials QM Anstee, EJ Lawitz, N Alkhouri, VWS Wong, M Romero‐Gomez, ... Hepatology 70 (5), 1521-1530, 2019 | 233 | 2019 |
| NASH in lean individuals R Younes, E Bugianesi Seminars in liver disease 39 (01), 086-095, 2019 | 233 | 2019 |
| Therapeutic pipeline in nonalcoholic steatohepatitis R Vuppalanchi, M Noureddin, N Alkhouri, AJ Sanyal Nature Reviews Gastroenterology & Hepatology 18 (6), 373-392, 2021 | 214 | 2021 |
| Acetyl-CoA carboxylase inhibitor GS-0976 for 12 weeks reduces hepatic de novo lipogenesis and steatosis in patients with nonalcoholic steatohepatitis EJ Lawitz, A Coste, F Poordad, N Alkhouri, N Loo, BJ McColgan, ... Clinical Gastroenterology and Hepatology 16 (12), 1983-1991. e3, 2018 | 197 | 2018 |
| Combination therapies including cilofexor and firsocostat for bridging fibrosis and cirrhosis attributable to NASH R Loomba, M Noureddin, KV Kowdley, A Kohli, A Sheikh, G Neff, ... Hepatology 73 (2), 625-643, 2021 | 187 | 2021 |
| Insulin sensitizer MSDC-0602K in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled phase IIb study SA Harrison, N Alkhouri, BA Davison, A Sanyal, C Edwards, JR Colca, ... Journal of hepatology 72 (4), 613-626, 2020 | 182 | 2020 |
